271 related articles for article (PubMed ID: 33612455)
21. Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients.
Fujiwara M; Tanaka H; Kobayashi M; Nakamura Y; Fan B; Ishikawa Y; Fukuda S; Toda K; Yoshida S; Yokoyama M; Yoshimura R; Fujii Y
Clin Genitourin Cancer; 2024 Apr; 22(2):193-200.e1. PubMed ID: 38000954
[TBL] [Abstract][Full Text] [Related]
22. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
[TBL] [Abstract][Full Text] [Related]
23. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Daneshmand S; Brummelhuis ISG; Pohar KS; Steinberg GD; Aron M; Cutie CJ; Keegan KA; Maffeo JC; Reynolds DL; Raybold B; Chau A; Witjes JA
Urol Oncol; 2022 Jul; 40(7):344.e1-344.e9. PubMed ID: 35431132
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer.
Marcq G; Souhami L; Cury FL; Salimi A; Aprikian A; Tanguay S; Vanhuyse M; Rajan R; Brimo F; Mansure JJ; Kassouf W
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):738-741. PubMed ID: 33421558
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V; Dirix P; Van Praet C; Berghen C; Albersen M; Junius S; Liefhooghe N; Noé L; De Meerleer G; Ost P; Villeirs G; Verbeke S; De Maeseneer D; Rammant E; Verghote F; Elhaseen E; De Man K; Decaestecker K
Eur Urol Focus; 2022 Sep; 8(5):1238-1245. PubMed ID: 34893458
[TBL] [Abstract][Full Text] [Related]
27. Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications.
Cohen S; Gal J; Freifeld Y; Khoury S; Dekel Y; Hofman A; Malshi K; Amiel G; Sagi I; Leibovici I; Golan S; Baniel J; Rozenzweig B; Dotan Z; Haifler M
Nutrients; 2021 Dec; 13(12):. PubMed ID: 34960023
[TBL] [Abstract][Full Text] [Related]
28. Systematic review of neoadjuvant therapy by immune checkpoint inhibitors before radical cystectomy: where do we stand?
Albisinni S; Aoun F; Diamand R; Mjaess G; Esperto F; Martinez Chanza N; Roumeguère T; De Nunzio C
Minerva Urol Nefrol; 2020 Dec; 72(6):663-672. PubMed ID: 32993274
[TBL] [Abstract][Full Text] [Related]
29. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Basile G; Bandini M; Gibb EA; Ross JS; Raggi D; Marandino L; Costa de Padua T; Crupi E; Colombo R; Colecchia M; Lucianò R; Nocera L; Moschini M; Briganti A; Montorsi F; Necchi A
Clin Cancer Res; 2022 Dec; 28(23):5107-5114. PubMed ID: 36190522
[TBL] [Abstract][Full Text] [Related]
31. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
32. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
Jackson-Spence F; Toms C; O'Mahony LF; Choy J; Flanders L; Szabados B; Powles T
Future Oncol; 2023 Mar; 19(7):509-515. PubMed ID: 37082935
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity.
Johnson DC; Nielsen ME; Matthews J; Woods ME; Wallen EM; Pruthi RS; Milowsky MI; Smith AB
BJU Int; 2014 Aug; 114(2):221-8. PubMed ID: 24274722
[TBL] [Abstract][Full Text] [Related]
34. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
[TBL] [Abstract][Full Text] [Related]
35. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
[No Abstract] [Full Text] [Related]
36. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Powles T; Assaf ZJ; Degaonkar V; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Sethi H; Aleshin A; Shi Y; Davarpanah N; Carter C; Bellmunt J; Mariathasan S
Eur Urol; 2024 Feb; 85(2):114-122. PubMed ID: 37500339
[TBL] [Abstract][Full Text] [Related]
37. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study.
Kitamura H; Hinotsu S; Tsukamoto T; Shibata T; Mizusawa J; Kobayashi T; Miyake M; Nishiyama N; Kojima T; Nishiyama H;
Jpn J Clin Oncol; 2020 Dec; 50(12):1464-1469. PubMed ID: 32699909
[TBL] [Abstract][Full Text] [Related]
38. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
[TBL] [Abstract][Full Text] [Related]
39. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
[TBL] [Abstract][Full Text] [Related]
40. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]